Dependent on the IgG1 or IgG4 subclass, and directly correlating with the EGFR expression levels in the tested cell lines (A431 ≫ HT29 > CaCo2), the α-EGFR therapeutic anti-tumor antibody cetuximab displayed different capacity to trigger phagocytosis of tumor cells by human monocytes (Repository Figure 5). This evidence concerns the gene EGFR and neoplasm.